-BPL has signed an agreement with a global company (Fortune500) to collaborate in the development of a new protein-based drug candidate.
According to the agreement, BPL will develop a bacterial fermentation, refolding process,
purification and formulation as well as the related analytical testing methods.
For this project, BPL will utilize its know-how and experience in recombinant protein expression in bacterial systems, purification and product formulation.
-BPL has signed an agreement with US based company for the development and production of series of enzymes and their immobilization to solid matrices. BPL will utilize its know-how and experience in recomninant enzyme expression in bacterial systems, purification and product formulation.
-BPL is relocating to a new facility in Yavne- 15 Nahal Snir st. The facility, designed and constructed specially according to BPL's plans and requirements, will be ready by ebd December 2017. BPL will start operation in the new facility by beginning January 2018.
Hepatocyte growth factor (expressed in mammalian cells), also known as Hepatopoietin A, is mitogenic for a variety of cell types, including endothelial and epithelial cells, melanocytes, and keratinocytes. It is identical to scatter factor, a fibroblast-derived soluble factor that promotes the dissociation of epithelial and vascular endothelial cell colonies in monolayer cultures by stimulating cell migration. HGF is secreted as an inactive single chain precursor and is converted to the heterodimeric active form by HGF activator.
BPL Biologics 19 Hidekel st. Yavne POB 13240 8122614 Israel Tel: +972.76.548.8118 US: +973.723.9000